**Appendix Table D54. Risk of bias in randomized controlled clinical trials that examined calcium channel antagonists for migraine prevention in adults**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Reference** | **Masking of the Treatment Status** | **Intention to Treat Analysis Preplanned** | **Allocation Concealment** | **Adequacy of Randomization** | **Selective Outcome Reporting** | **Risk of Bias** |
| Markley, 1984124 | Double blind | No | Unclear | Not reported | No | Medium |
| Stewart, 1988125 | Double blind | No | Unclear | Unclear | Unclear | Medium |
| Leandri, 1990126 | Double blind | No | Unclear | Yes | No | Medium |
| Gelmers, 1983127 | Double blind | No | Unclear | Yes | No | Medium |
| Migraine-Nimodipine European Study Group, 1989128 | Double blind | Yes | Unclear | No, migraine index different between nimodipine and placebo groups | No | Medium |
| McArthur, 1989129 | Double blind | No | Unclear | No, migraine index different between nimodipine and placebo groups | No | High |
| Solomon, 1983130 | Double blind | No | Unclear | Unclear | No | Medium |
| Meyer, 1983131 | Double blind | No | Unclear | Unclear | No | Medium |
| Havanka-Kanniainen, 1985132 | Double blind | No | Unclear | Unclear | No | Medium |
| Migraine-Nimodipine European Study Group, 1989133 | Double blind | Yes | Unclear | Yes | No | Low |
| Ansell, 1988134 | Double blind | No | Unclear | Unclear, more classical migraine in active group | No | Medium |
| Shukla, 1995135 | Double blind | No | Unclear | Unclear | No | Medium |